Cargando…

Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab

Over the past decade, the emergence of immune checkpoint inhibitors has brought about significant change to the treatment landscape of bladder cancer. Nivolumab is an immune checkpoint inhibitor that has shown favorable results resulting in FDA approval for treatment of platinum-refractory locally a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiang, Ryan S, Glover, Michael J, Khaki, Ali Raza, Srinivas, Sandy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582299/ https://www.ncbi.nlm.nih.gov/pubmed/36275184 http://dx.doi.org/10.2147/OTT.S369043

Ejemplares similares

Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease
por: Dietrich, Brian, et al.
Publicado: (2018)

Immunotherapy for Urothelial Carcinoma: Current Status and Perspectives
por: Kitamura, Hiroshi, et al.
Publicado: (2011)

Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
por: Benjamin, David J, et al.
Publicado: (2022)

Immunotherapy in urothelial carcinoma: fade or future standard?
por: Breyer, Johannes, et al.
Publicado: (2016)

Clinical utility of nivolumab in the treatment of advanced melanoma
por: Asmar, Ramsey, et al.
Publicado: (2016)

Clinical Utility of Cxbladder for the Diagnosis of Urothelial Carcinoma
por: Darling, David, et al.
Publicado: (2017)

Aristolochic Acid and Immunotherapy for Urothelial Carcinoma: Directions for unmet Needs
por: Yang, Huang-Yu, et al.
Publicado: (2019)

Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer: A Systematic Review
por: Sharp, John, et al.
Publicado: (2021)

Clinical Evaluation of Avelumab in the Treatment of Advanced Urothelial Carcinoma: Focus on Patient Selection and Outcomes
por: Ten Eyck, Jennifer E, et al.
Publicado: (2022)

Nivolumab-Induced Pneumonitis in a Patient With Urothelial Cancer
por: Kasi, Arbab Furquan Ud din, et al.
Publicado: (2023)

Focus on Nivolumab in NSCLC
por: Cortinovis, Diego L., et al.
Publicado: (2016)

Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder
por: Kim, Hongsik, et al.
Publicado: (2023)

Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin
por: Shafique, Muhammad Ashir, et al.
Publicado: (2023)

Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy
por: Kim, Ryul, et al.
Publicado: (2022)

Emerging treatment options for the management of Hodgkin’s lymphoma: clinical utility of nivolumab
por: Bond, David A, et al.
Publicado: (2017)

Wnt/β-Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2021)

Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?
por: Renner, Alex, et al.
Publicado: (2021)

Current status of the focused series “Urothelial Carcinoma”
por: Yuk, Hyeong Dong, et al.
Publicado: (2020)

Updates on the Pivotal Roles of Mitochondria in Urothelial Carcinoma
por: Huang, Chiang-Chi, et al.
Publicado: (2022)

Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma
por: Ning, Yang‐Min, et al.
Publicado: (2017)

Glycogen Metabolism Predicts the Efficacy of Immunotherapy for Urothelial Carcinoma
por: Zhang, Yueming, et al.
Publicado: (2021)

Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy
por: Anraku, Tsutomu, et al.
Publicado: (2023)

Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma
por: Danno, Tetsuya, et al.
Publicado: (2021)

Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma
por: Shao, Zhiying, et al.
Publicado: (2016)

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
por: Apolo, Andrea B., et al.
Publicado: (2020)

Role of immunotherapy in localized muscle invasive urothelial cancer
por: Kaur, Jasmeet, et al.
Publicado: (2021)

Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
por: Zhu, Jason, et al.
Publicado: (2018)

Immunological effects of nivolumab immunotherapy in patients with oral cavity squamous cell carcinoma
por: Xiong, Ying, et al.
Publicado: (2020)

Hypoxic Characteristic Genes Predict Response to Immunotherapy for Urothelial Carcinoma
por: Hong, Shuo, et al.
Publicado: (2021)

Case Report: Pseudoprogression With Nivolumab and Bevacizumab Followed by Recurrent Immune-Related Pneumonitis in Urothelial Carcinoma With Lung Metastasis
por: Yang, Zizhong, et al.
Publicado: (2021)

Checkmate 274 trial: Is Nivolumab the new standard in adjuvant setting for high-risk muscle invasive urothelial carcinoma?
por: Kumar, Naveen
Publicado: (2021)

Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Onychopathy Induced by Nivolumab: A Targeted Immunotherapy
por: Zahoor, Fatima, et al.
Publicado: (2022)

Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy
por: Benjamin, David J., et al.
Publicado: (2023)

Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
por: Guo, Liting, et al.
Publicado: (2017)

Immune escape mechanisms and immunotherapy of urothelial bladder cancer
por: Yang, Zhao, et al.
Publicado: (2021)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
por: Galsky, Matthew D, et al.
Publicado: (2021)

Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review
por: Kim, Tae Jin, et al.
Publicado: (2020)

Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions
por: Gupta, Shilpa, et al.
Publicado: (2017)

Do Cancer Genetics Impact Treatment Decision Making? Immunotherapy and Beyond in the Management of Advanced and Metastatic Urothelial Carcinoma
por: Hui, Gavin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a3semnrpmseke2tmm5jgqo03ss